

Newsletter from Emotra AB (publ)

Göteborg, November 27, 2018

Emotra: Agreement with Italian research group

Emotra AB (“Emotra”) is pleased to announce that we have reached an agreement with an Italian research group concerning so-called “research rental”. This Italian research team aims to carry out a study and has asked for Emotra’s support in the form of hardware, systems and know-how concerning electrodermal measurements. This research team does not work with the problem of suicide. Instead, they wish to determine whether Emotra’s technology can be used within a completely different clinical indication area. The research group will be paying for their access to our functionality and support during the project period.

For Emotra, research on electrodermal reactivity and EDOR-testing is of strategic importance. The company encourages and supports those clinics and research institutes that are interested in and that have the capacity to work with our technology in order to share and develop this knowledge with more people.

Through this arrangement, which is one of many examples of how Emotra works with research on our technology and methodology, the Italian researchers will rent the system and we will support them with our know-how on how to use it. The goal of this arrangement is to shorten these researchers’ learning curve and give them greater planning flexibility, since they are not sure how long their project will last. At present, we cannot place a financial value on this deal, since that value depends on the project’s scope and timeframe.

From Emotra’s perspective, the most valuable part of this arrangement is that more and more research groups choose to use the company’s technology to study psychologically-related problems.

For further information about the Company, please contact:

Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden
Tel: +46 73 234 41 93, www.emotra.se